BioCentury
ARTICLE | Clinical News

Zavicefta ceftazidime/avibactam: Phase III data

August 1, 2016 7:00 AM UTC

Top-line data from the double-blind, double-dummy, international Phase III REPROVE trial in 879 patients with HAP, including VAP, showed that 2,000 mg/500 mg IV Zavicefta ceftazidime/avibactam as a 2-...